Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Short term Debt: 2022

Historic Short term Debt for Denali Therapeutics (DNLI) over the last 1 years, with Dec 2022 value amounting to $4.4 million.

  • Denali Therapeutics' Short term Debt was N/A to $4.4 million in Q4 2022 from the same period last year, while for Dec 2022 it was $4.4 million, marking a year-over-year change of. This contributed to the annual value of $4.4 million for FY2022, which is N/A change from last year.
  • According to the latest figures from Q4 2022, Denali Therapeutics' Short term Debt is $4.4 million, which was up 204.09% from $1.4 million recorded in Q3 2022.
  • Over the past 5 years, Denali Therapeutics' Short term Debt peaked at $4.4 million during Q4 2022, and registered a low of $1.4 million during Q3 2022.
  • In the last 1 years, Denali Therapeutics' Short term Debt had a median value of $2.7 million in 2022 and averaged $2.8 million.